Following submission of CAPA plan in response to two Form 483 observations
Alkem Laboratories announced that the Company had submitted a detailed corrective and preventive action (CAPA) plan to the USFDA within the stipulated timelines in response to two Form 483 observations issued by the regulator. The inspection of the company's manufacturing facility at Baddi has now been closed by the US FDA.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
